An association study between catalase -262C>T gene polymorphism, sodium-lithium countertransport activity, insulin resistance, blood lipid parameters and their response to atorvastatin, in Greek dyslipidaemic patients and normolipidaemic controls.
This study attempted to examine the effect of a functional catalase gene polymorphism, CAT -262C>T, on sodium-lithium countertransport (Na-Li CT) activity, insulin resistance determined as the homeostasis model assessment index (HOMA-IR), blood lipid parameters (cholesterol, triglycerides, low density lipoprotein cholesterol, high density lipoprotein cholesterol, apolipoprotein B, apolipoprotein A-I) and their response to atorvastatin, in previously characterized Greek dyslipidaemic patients and normolipidaemic controls. Putative associations were examined by running univariate analyses with a general linear model, using age, sex, smoking and hypertension as covariates. While no statistically significant associations were detected between the CAT -262C>T polymorphism and either baseline values or their modulation by atorvastatin in the patient group, HOMA-IR values were significantly (p=0.028) lower among CAT -262CC controls compared to their T allele carrier counterparts. A trend towards higher plasma triglyceride values among CAT -262CC genotypes was also detected, in both dyslipidaemic patients and normolipidaemic controls.
Kosmidou
Maria
M
1st Propedeutic Clinic, AHEPA University Hospital, Aristotle University Medical School, Thessaloniki 54124, Greece.
Hatzitolios
Apostolos I
AI
Molyva
Dimitra
D
Raikos
Nikolaos
N
Savopoulos
Christos
C
Daferera
Niki
N
Kokkas
Vassileios
V
Goulas
Antonis
A
D000328:Adult; D000483:Alleles; D017920:Antiporters / Q000097:blood*; D000069059:Atorvastatin; D016022:Case-Control Studies; D002374:Catalase / Q000235:genetics*; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006115:Greece; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D007333:Insulin Resistance / Q000235:genetics*; D016014:Linear Models; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011758:Pyrroles / Q000494:pharmacology*; D012189:Retrospective Studies
D017920:Antiporters; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011758:Pyrroles; C045885:sodium-lithium countertransporter; D000069059:Atorvastatin; D002374:Catalase